Search

A study conducted at Paracelsus Medical University Salzburg compared the new Amicus Blue inline system with two established systems for extracorporeal photopheresis (ECP) in terms of cell yield and collection efficiency. The research found that the Therakos inline system had the highest collection efficiency, while the Spectra Optia offline system yielded the highest amount of collected mononuclear cells (MNCs). The study concluded that while the Amicus Blue system collected sufficient MNCs for ECP, it had lower collection efficiency and yielded fewer cells compared to the other systems. [Extracted from the article]

The article discusses the use of Extracorporeal Photopheresis (ECP) as an immunomodulatory therapy in solid organ transplantation to prevent rejection. Current immunosuppressive therapies have adverse effects, prompting the need for alternative treatments. ECP shows promise in reducing the need for immunosuppression and supporting graft tolerance, particularly in high-risk patients. The research was conducted at the University Medical Center Hamburg-Eppendorf and received financial support from Mallinckrodt Pharmaceuticals. [Extracted from the article]

The article discusses a clinical trial, NCT06646016, focusing on the use of UVADEX in conjunction with extracorporeal photopheresis (ECP) for immune-related colitis induced by immune checkpoint inhibitor therapy in melanoma or NSCLC patients. The study aims to evaluate the efficacy of this treatment compared to the best available therapy (BAT) for participants with inadequate response to steroids. The trial involves specific outcome measures related to remission of colitis, resolution of symptoms, and survival rates, with a completion date set for February 6, 2026. [Extracted from the article]

A new report from G. Papanicolaou Hospital in Thessaloniki, Greece, discusses the use of extracorporeal photopheresis (ECP) as a non-immunosuppressive treatment for graft-versus-host disease (GvHD) in patients who have undergone allogeneic hematopoietic cell transplantation (allo-HCT). The study found that ECP was effective in treating both acute and chronic GvHD, with a high response rate in patients with severe acute GvHD. The reduction in immunosuppression and the number of ECP sessions were associated with improved overall survival. The researchers concluded that ECP is a safe and effective treatment for GvHD and further investigation is needed to optimize its use. [Extracted from the article]

Fenwal Inc. has been issued a patent for systems and methods for treating a biological fluid with light in the event of a bulb outage. The patent describes an irradiation device that is used in the treatment of biological fluids, such as blood and blood products, with photochemical agents for the inactivation of viruses, bacteria, and other contaminants. The device includes an array of multiple light sources and sensors to measure the intensity of light being delivered to the cells. In the event of a bulb outage, the device is designed to continue the photoactivation procedure by adjusting the duration of the light treatment or the intensity of the light emitted by the remaining light sources. [Extracted from the article]

A patent application has been submitted for the use of adiponectin, alone or in combination with extracorporeal photopheresis (ECP), to treat immune-related adverse events (irAEs) caused by immune checkpoint inhibitors (ICBs). ICBs are used in cancer treatment to boost the immune system's response to tumors, but they can also cause immune-mediated tissue damage. Current treatment options for irAEs, such as glucocorticosteroids, can have negative effects on the anti-tumor immune response. The inventors found that adiponectin and ECP therapy could successfully treat irAEs without interfering with the anti-tumor effects of ICBs. [Extracted from the article]

A recent study conducted by the Chinese Academy of Medical Sciences investigated the effects of extracorporeal photopheresis (ECP) on preventing acute graft-versus-host disease (aGVHD) in mice. The study found that ECP-induced early apoptotic splenic mononuclear cells were able to reduce the occurrence of aGVHD by decreasing the Th1 response in mice. The research concluded that ECP shows promise as a preventive measure for aGVHD. Further information on this study can be found in the journal article "Effect and mechanism of extracorporeal photopheresis on preventing acute graft versus host disease in mice." [Extracted from the article]

Researchers at the University Hospital of Siena have published a study on the use of extracorporeal photopheresis (ECP) as a therapy for chronic lung allograft dysfunction (CLAD) in lung transplant patients. They developed a web-based data collection tool to gather pre- and post-transplant data on patients undergoing ECP. The study found that ECP led to a significant improvement in lung function in some patients, particularly those without recurrent respiratory infections. The researchers concluded that informatics is an important tool in medical science and can improve patient outcomes. [Extracted from the article]

A recent study conducted at Trondheim University Hospital in Norway has explored the use of 5-aminolevulinic acid (ALA) in conjunction with light, known as ALA-based photodynamic therapy, as a potential treatment for cutaneous T-cell lymphoma (CTCL). The study found that ALA-ECP treatment was safe and well-tolerated, with no significant changes in vital signs and only two non-serious adverse events reported. Additionally, the treatment resulted in a 53% reduction in skin involvement and a 50% reduction in pruritus. These findings suggest that ALA-ECP may be a promising therapeutic option for CTCL patients. [Extracted from the article]

A recent report from the University of Angers in France discusses the potential use of extracorporeal photopheresis (ECP) as a technique to modify immunosuppression in solid organ transplantation (SOT). The researchers highlight the current unmet medical need for effective strategies to minimize the side effects of immunosuppressive therapies, which can include infection, malignancy, cardiovascular diseases, and nephrotoxicity. The review examines the available literature on ECP and its potential benefits in heart, lung, kidney, and liver transplantation, noting improvements in rejection, allograft survival, and associated side effects. However, the researchers emphasize the need for further high-quality research, particularly randomized control trials, in this area. [Extracted from the article]

A recent study conducted by researchers at Fondazione IRCCS Policlinico San Matteo has explored the molecular mechanisms behind the effects of Extracorporeal Photopheresis (ECP) on patients with Chronic Lung Allograft Dysfunction (CLAD) following lung transplantation. The study found that ECP may affect regulatory T cell functions and down modulate the release of connective tissue growth factor (CTGF). These findings suggest that ECP could potentially improve or stabilize graft function in CLAD patients. Further research is needed to fully understand the mechanisms and potential benefits of ECP in this context. [Extracted from the article]

A recent report from the University of Alabama at Birmingham discusses the use of extracorporeal photopheresis (ECP) in the treatment of dermatological diseases. ECP is a procedure commonly used for T-cell lymphoma, but it has also been tested for autoimmune conditions, including dermatologic diseases. The research highlights the potential of ECP to modify leukocytes and alter cytokine production, but notes that more evidence is needed to determine its efficacy in treating these dermatologic diseases. The report provides a review of the literature on ECP and discusses its applications, guidelines, recommendations, and future implementation for dermatologic diseases. [Extracted from the article]

Researchers from the University Medical Center Hamburg-Eppendorf have reported on successful treatment for refractory checkpoint inhibitor-induced hepatitis. Immune checkpoint inhibitors have been effective in treating malignant melanoma, but they can also lead to immune-related adverse events such as hepatitis. In this case, a 39-year-old woman with metastatic melanoma was successfully treated with a combination therapy consisting of prednisolone, mycophenolate-mofetil, extracorporeal photopheresis, and infliximab. This research provides valuable insights into the treatment of immune-mediated hepatitis caused by checkpoint inhibitors. [Extracted from the article]

A new report from the Fred Hutchinson Cancer Research Center in Seattle discusses the use of extracorporeal photopheresis (ECP) for the treatment of various immune-related conditions. The study compares the use of heparin and acid citrate dextrose-A (ACDA) as anticoagulants during ECP treatment. The research found that overall, the ECP system performed similarly with both anticoagulants, but ACDA showed potential benefits in reducing variability in photoactivation time. The study was supported by Mallinckrodt Pharmaceuticals and has been peer-reviewed. [Extracted from the article]

A recent report from the University of Lausanne in Switzerland discusses the use of extracorporeal photopheresis (ECP) as a first-line immunomodulatory therapy for leukaemic cutaneous T-cell lymphoma (L-CTCL). The study aimed to investigate the effects of ECP on cytokine secretion patterns in patients with L-CTCL to better understand its mechanism of action. The researchers found that ECP stimulates the innate immune network and facilitates a boost in relevant innate immune cytokines, which can be used as biomarkers of response to ECP in patients with L-CTCL. This research provides valuable insights into the potential benefits of ECP in treating L-CTCL. [Extracted from the article]

Researchers from the University Clinic in Heidelberg, Germany have found that extracorporeal photopheresis (ECP) shows promise in treating graft-versus-host disease (GvHD) after CAR-T cell therapy. GvHD occurs in a significant number of patients receiving CAR-T cells after stem cell transplantation. ECP was found to reduce the alloreactivity of CAR-T cells without compromising their functionality. This research suggests that ECP could be a promising treatment strategy for GvHD after CAR-T cell therapy. [Extracted from the article]

A patent has been issued to Fenwal Inc. for systems and methods for photoactivation of a biological fluid. The patent describes an irradiation device that can be used in the treatment of blood products, such as red blood cells and white blood cells, with a photochemical agent activated by light. The device includes multiple light sources, light energy sensors, and a programmable controller to deliver a targeted light dose. The invention addresses the challenge of accounting for light-attenuating cellular material and variations in light intensity during treatment. This patent provides valuable information for researchers interested in the development of improved methods for extracorporeal photopheresis procedures. [Extracted from the article]

A study conducted at the University Medical Center Mannheim in Germany has found that a combination therapy of mogamulizumab and extracorporeal photopheresis (ECP) is an effective treatment for erythrodermic cutaneous T-cell lymphoma (CTCL). The study included 11 patients with CTCL who received this combination therapy, and it resulted in an overall response rate of 73% in the skin and 64% in the blood. The therapy was well-tolerated, with common adverse events including mogamulizumab-associated rash, anemia, lymphocytopenia, and infusion-related reactions. This research provides new treatment options for CTCL patients and highlights the importance of combination therapies in managing this rare lymphoproliferative malignancy. [Extracted from the article]

A recent study conducted by researchers at Johns Hopkins University explores the use of mogamulizumab, a monoclonal antibody, in combination with other therapies for the treatment of cutaneous T-cell lymphoma (CTCL). The study found that the combination therapy resulted in positive treatment responses and durable outcomes for patients, with minimal adverse effects. The researchers suggest that this multimodality approach warrants further investigation and confirmation. This information may be valuable for individuals researching CTCL and seeking alternative treatment options. [Extracted from the article]

A report from Newcastle University in the United Kingdom discusses the need for effective treatments for chronic lung rejection, also known as chronic lung allograft dysfunction (CLAD), following lung transplantation. The report evaluates the use and efficacy of lymphocyte depleting and immunomodulating therapies in progressive CLAD, including anti-thymocyte globulin, alemtuzumab, methotrexate, cyclophosphamide, total lymphoid irradiation, and extracorporeal photopheresis. The researchers suggest that extracorporeal photopheresis, anti-thymocyte globulin, and total lymphoid irradiation are currently the most viable second-line treatment options for progressive CLAD patients. However, the lack of randomized controlled trials limits the interpretation of the results. [Extracted from the article]

This document provides information about a clinical trial that is not yet recruiting participants. The trial aims to evaluate the effectiveness of a treatment for acute graft-versus-host disease (GVHD) in patients who have undergone allogeneic hematopoietic stem cell transplantation. The treatment involves a combination of extracorporeal photopheresis (ECP) and steroids. The trial will enroll 42 participants and is expected to be completed in January 2026. The eligibility criteria for participants are outlined, and the responsible party for the trial is the Central Hospital in Nancy, France. [Extracted from the article]

A recent study conducted by researchers at Tehran University of Medical Sciences in Iran explored the cellular resistance process in treated cells through extracorporeal photopheresis (ECP). ECP is a therapeutic method used for diseases such as cancers, particularly leukemic cutaneous T-cell lymphoma (CTCL). The researchers analyzed data from the Gene Expression Omnibus (GEO) database and identified 57 significant differentially expressed genes (DEGs) related to ECP treatment. They found that 15 histones from the H2A, H2B, and H3 families, especially the H2A family, played a crucial role in the resistance property of the treated cells. The study suggests that sensitivity to ECP treatment depends on molecular events involving histones. [Extracted from the article]

Toronto, Canada, North and Central America, Graft-Versus-Host Disease, Health and Medicine, Immune System Diseases and Conditions, PUVA Therapy, Photopheresis, Phototherapy, Risk and Prevention, Transplantation Keywords: Toronto; Canada; North and Central America; Graft-Versus-Host Disease; Health and Medicine; Immune System Diseases and Conditions; PUVA Therapy; Photopheresis; Phototherapy; Risk and Prevention; Transplantation EN Toronto Canada North and Central America Graft-Versus-Host Disease Health and Medicine Immune System Diseases and Conditions PUVA Therapy Photopheresis Phototherapy Risk and Prevention Transplantation 426 426 1 11/06/23 20231109 NES 231109 2023 NOV 9 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Data detailed on Immune System Diseases and Conditions - Graft-Versus-Host Disease have been presented. [Extracted from the article]

Extracorporeal Photopheresis (ECP) is a treatment for Cutaneous T-Cell Lymphoma that uses UVA light and a photoactivated drug called 8-methoxypsoralen. However, 25% of patients do not respond to this treatment, and the reasons for this are unknown. This study investigated the effects of UVA light and 8-methoxypsoralen on platelets and extracellular vesicles (EVs) in vitro. The researchers found that this treatment did not activate platelets or significantly alter levels of platelet activation markers or EVs. Further research is needed to confirm these findings in vivo. [Extracted from the article]

The news correspondents obtained a quote from the research from Osaka University, "In recent years, the use of a light emitting diode (LED) in the clinic has attracted considerable interest. Keywords: Osaka; Japan; Asia; Drug Research; Cell Proliferation; Electronics; Health and Medicine; Light-emitting Diode; PUVA Therapy; Photopheresis; Phototherapy EN Osaka Japan Asia Drug Research Cell Proliferation Electronics Health and Medicine Light-emitting Diode PUVA Therapy Photopheresis Phototherapy 2192 2192 1 10/30/23 20231103 NES 231103 2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Research findings on Drug Research are discussed in a new report. [Extracted from the article]

Keywords: Buenos Aires; Argentina; South America; Antifungals; Antiinfectives; Azole Antifungals; Bone Marrow Cells; Drugs and Therapies; Graft-Versus-Host Disease; Health and Medicine; Hematopoietic Stem Cells; Immune System Diseases and Conditions; PUVA Therapy; Pediatrics; Pharmaceuticals; Photopheresis; Phototherapy; Stem Cell Research; Voriconazole Therapy EN Buenos Aires Argentina South America Antifungals Antiinfectives Azole Antifungals Bone Marrow Cells Drugs and Therapies Graft-Versus-Host Disease Health and Medicine Hematopoietic Stem Cells Immune System Diseases and Conditions PUVA Therapy Pediatrics Pharmaceuticals Photopheresis Phototherapy Stem Cell Research Voriconazole Therapy 302 302 1 10/30/23 20231103 NES 231103 2023 NOV 4 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Week -- New research on Immune System Diseases and Conditions - Graft-Versus-Host Disease is the subject of a report. For more information on this research see: Treatment of graft versus host disease with photopheresis interferes in voriconazole therapeutic drug monitoring: A case study. [Extracted from the article]

Findings from University of Pittsburgh Update Knowledge of Mycosis Fungoides (What Does the Future Hold for Biomarkers of Response To Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?) Keywords for this news article include: Pittsburgh, Pennsylvania, United States, North and Central America, Biomarkers, Cancer, Cutaneous Lymphoma, Dermatology, Diagnostics and Screening, Health and Medicine, Lymphoproliferative Diseases and Conditions, Lymphoproliferative Disorders, Mycosis Fungoides, Oncology, PUVA Therapy, Photopheresis, Phototherapy, T-Cell, University of Pittsburgh. Keywords: Pittsburgh; State:Pennsylvania; United States; North and Central America; Biomarkers; Cancer; Cutaneous Lymphoma; Dermatology; Diagnostics and Screening; Health and Medicine; Lymphoproliferative Diseases and Conditions; Lymphoproliferative Disorders; Mycosis Fungoides; Oncology; PUVA Therapy; Photopheresis; Phototherapy; T-Cell EN Pittsburgh State:Pennsylvania United States North and Central America Biomarkers Cancer Cutaneous Lymphoma Dermatology Diagnostics and Screening Health and Medicine Lymphoproliferative Diseases and Conditions Lymphoproliferative Disorders Mycosis Fungoides Oncology PUVA Therapy Photopheresis Phototherapy T-Cell 958 958 1 10/30/23 20231031 NES 231031 2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Researchers detail new data in Lymphoproliferative Diseases and Conditions - Mycosis Fungoides. [Extracted from the article]

Keywords: Adrenal Cortical Steroids; Antineoplastics; Antirheumatics; Biomedicine; Biotechnology; Cell Transplantation; Cell Transplants; Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Etanercept Therapy; Globulins; Glucocorticoids; Graft-Versus-Host Disease; Health and Medicine; Hormones; Immune System Diseases and Conditions; Immune System Diseases and Conditions - Graft-Versus-Host Disease; Immunologic Agents; Infliximab Therapy; Metabolism; Monoclonal Antibodies; PUVA Therapy; Pediatrics; Peptides and Proteins; Pharmaceuticals; Photopheresis; Phototherapy; Prednisone Therapy; Proteins; Quality of Life; Stem Cell Research; Surgery; Transplant Medicine; Tumor Necrosis Factor (TNF) Inhibitors; Wellness EN Adrenal Cortical Steroids Antineoplastics Antirheumatics Biomedicine Biotechnology Cell Transplantation Cell Transplants Clinical Research Clinical Trials and Studies Drugs and Therapies Etanercept Therapy Globulins Glucocorticoids Graft-Versus-Host Disease Health and Medicine Hormones Immune System Diseases and Conditions Immune System Diseases and Conditions - Graft-Versus-Host Disease Immunologic Agents Infliximab Therapy Metabolism Monoclonal Antibodies PUVA Therapy Pediatrics Peptides and Proteins Pharmaceuticals Photopheresis Phototherapy Prednisone Therapy Proteins Quality of Life Stem Cell Research Surgery Transplant Medicine Tumor Necrosis Factor (TNF) Inhibitors Wellness 468 468 1 10/24/23 20231024 NES 231024 2023 OCT 26 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Staff editors report on the newly launched clinical trial, NCT06075706, which has the following summary description: "The purpose of this trial is the comparative evaluation of overall response rate (ORR) in paediatric participants with steroid-refractory acute graft-versus-host disease (SR-aGvHD) at Visit Day 28 after treatment with MC0518 or first used best available therapy (BAT).". [Extracted from the article]

Keywords: Biomarkers; Cancer; Cutaneous Lymphoma; Dermatology; Diagnostics and Screening; Health and Medicine; Immunoproliferative Disorders; Lymphatic Diseases and Conditions; Lymphoproliferative Diseases and Conditions; Lymphoproliferative Disorders; Mycosis Fungoides; Oncology; PUVA Therapy; Photopheresis; Phototherapy; Sezary Syndrome; T-Cell EN Biomarkers Cancer Cutaneous Lymphoma Dermatology Diagnostics and Screening Health and Medicine Immunoproliferative Disorders Lymphatic Diseases and Conditions Lymphoproliferative Diseases and Conditions Lymphoproliferative Disorders Mycosis Fungoides Oncology PUVA Therapy Photopheresis Phototherapy Sezary Syndrome T-Cell 2138 2138 1 10/09/23 20231010 NES 231010 2023 OCT 13 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on Sezary syndrome. Biomarkers, Cancer, Cutaneous Lymphoma, Dermatology, Diagnostics and Screening, Health and Medicine, Immunoproliferative Disorders, Lymphatic Diseases and Conditions, Lymphoproliferative Diseases and Conditions, Lymphoproliferative Disorders, Mycosis Fungoides, Oncology, PUVA Therapy, Phototherapy, Photopheresis, T-Cell, Sezary Syndrome. [Extracted from the article]

Leukocytes frozen the day after ECP treatment had 1 week and 1 month WBC viabilities of 84.0 +/- 4.1 and 83.1 +/- 2.1, respectively. Keywords: Salt Lake City; State:Utah; United States; North and Central America; Apoptosis; Blood Cells; Cell Research; Cellular Physiology; Health and Medicine; Immunology; Leukocytes; PUVA Therapy; Photopheresis; Phototherapy EN Salt Lake City State:Utah United States North and Central America Apoptosis Blood Cells Cell Research Cellular Physiology Health and Medicine Immunology Leukocytes PUVA Therapy Photopheresis Phototherapy 2978 2978 1 08/21/23 20230825 NES 230825 2023 AUG 25 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in Cellular Physiology - Apoptosis. [Extracted from the article]

Keywords: Linkoping; Sweden; Europe; Graft-Versus-Host Disease; Health and Medicine; Immune System Diseases and Conditions; PUVA Therapy; Photopheresis; Phototherapy; Transplantation EN Linkoping Sweden Europe Graft-Versus-Host Disease Health and Medicine Immune System Diseases and Conditions PUVA Therapy Photopheresis Phototherapy Transplantation 176 176 1 07/24/23 20230727 NES 230727 2023 JUL 27 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Investigators publish new report on Immune System Diseases and Conditions - Graft-Versus-Host Disease. The news reporters obtained a quote from the research from Linkoping University, "We identified 2708 patients aged & GE; 18 years with a record of allogeneic hematopoietic stem cell transplantation (HSCT) in the Swedish Patient Register between 2006 and 2020. [Extracted from the article]

Keywords: Biomarkers; Cancer; Cutaneous T-Cell Lymphoma; Cytokines; Diagnostics and Screening; Health and Medicine; Hematology; Immunoproliferative Disorders; Intercellular Signaling Peptides and Proteins; Lymphatic Diseases and Conditions; Lymphoma; Lymphoproliferative Disorders; Oncology; PUVA Therapy; Photopheresis; Phototherapy; T-Cell Lymphoma EN Biomarkers Cancer Cutaneous T-Cell Lymphoma Cytokines Diagnostics and Screening Health and Medicine Hematology Immunoproliferative Disorders Intercellular Signaling Peptides and Proteins Lymphatic Diseases and Conditions Lymphoma Lymphoproliferative Disorders Oncology PUVA Therapy Photopheresis Phototherapy T-Cell Lymphoma 238 238 1 07/24/23 20230728 NES 230728 2023 JUL 24 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Fresh data on cutaneous T-cell lymphoma are presented in a new report. For more information on this research see: Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in leukaemic cutaneous T-cell lymphoma patients. [Extracted from the article]

Keywords: Blood Components; Business; Fenwal Inc.; Health and Medicine; Hematology; PUVA Therapy; Photopheresis; Phototherapy; Risk and Prevention EN Blood Components Business Fenwal Inc. Health and Medicine Hematology PUVA Therapy Photopheresis Phototherapy Risk and Prevention 679 679 1 07/10/23 20230714 NES 230714 2023 JUL 13 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Fenwal Inc. (Lake Zurich, Illinois, United States) has been issued patent number 11678825, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. The method includes programming a photopheresis system for pausing a photopheresis procedure to allow for the collection of blood sample at selected time intervals. [Extracted from the article]

Keywords: Clinical Pathology; Health and Medicine; Hospitals; PUVA Therapy; Photopheresis; Phototherapy EN Clinical Pathology Health and Medicine Hospitals PUVA Therapy Photopheresis Phototherapy 7752 7752 1 06/19/23 20230623 NES 230623 2023 JUN 23 (NewsRx) -- By a News Reporter-Staff News Editor at Health Insurance Week -- Researchers detail new data in clinical pathology. Clinical Pathology, Health and Medicine, Hospitals, PUVA Therapy, Photopheresis, Phototherapy. [Extracted from the article]

"As used herein the term "blood sample" comprises all kinds of blood-derived samples, including blood-cell samples such as MNC samples that are generated from blood. "Preferably, the immunoregulatory NK cells for use in such a treatment or prevention have been generated by adding a photosensitizing agent to a sample derived from a blood sample of a human subject and subjecting the sample to irradiation. It surprisingly could be shown that administration of such a sample or cells comprised in such a sample that underwent the method of the invention to a subject that has received a checkpoint-inhibitor therapy is effective in preventing the occurrence of irAE and even in the treatment of irAE that is already established in the subject. "In preferred embodiments, the blood sample used for generating the immunoregulatory NK cells of the invention is from a subject that has received a checkpoint-inhibitor therapy and is suspected of developing or has developed symptoms of immune-related adverse events (irAE). [Extracted from the article]

Keywords: Asia; Business; Graft-Versus-Host Disease; Health and Medicine; Immune System Diseases and Conditions; Japan; Mallinckrodt PLC; PUVA Therapy; Pharmaceutical Companies; Photopheresis; Phototherapy; Transplantation EN Asia Business Graft-Versus-Host Disease Health and Medicine Immune System Diseases and Conditions Japan Mallinckrodt PLC PUVA Therapy Pharmaceutical Companies Photopheresis Phototherapy Transplantation 2023 MAR 23 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Mallinckrodt plc, (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, announced that Japan's National Health Insurance (NHI) system has approved reimbursement for the CELLEX(R) extracorporeal photopheresis (ECP) system for the treatment of steroid-resistant or -intolerant chronic graft versus host disease (cGvHD). "Chronic graft versus host disease is a highly debilitating disease with a significant impact to the health of these patients with limited treatment options in Japan. [Extracted from the article]

Biomarkers, Diagnostics and Screening, Health and Medicine, Immunology, PUVA Therapy, Photopheresis, Phototherapy Keywords: Biomarkers; Diagnostics and Screening; Health and Medicine; Immunology; PUVA Therapy; Photopheresis; Phototherapy EN Biomarkers Diagnostics and Screening Health and Medicine Immunology PUVA Therapy Photopheresis Phototherapy 5361 5361 1 03/23/23 20230310 NES 230310 2023 MAR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on biomarkers is the subject of a new report. [Extracted from the article]